The UK Medicines and Healthcare products Regulatory Agency (MHRA) has a long history as a valued contributor to the global regulatory ecosystem. This contribution has been realised not only through advancements in regulatory science, but also through acting as a point of reference for the regulatory decision-making of other regulators and by leveraging outcomes from trusted partners in the system to deliver regulatory decisions and facilitate access to innovative medicines for UK patients. This balance of acting as a reference and recognising expert outputs from others is now widely accepted as standard practice and can in fact be seen as a measure of regulatory maturity. We believe that this balance should be retained as a central part of the MHRA’s operating model moving forward.
As 2026 shapes up to an unpredictable year, our policy experts have provided more grounding for what the life sciences sector should expect over the next 12 months. This is the second and final part of our 2026 outlook series.
J.P. Morgan’s healthcare conference may be wrapped up, but it has set some tangible momentum and without doubt a more buoyant mood for global life sciences going into 2026.
An acknowledgment from Astrea Bioseparations celebrating LIB Therapeutics' achievement of FDA approval for LEROCHOL™, including some collaboration efforts.
As we settle into the rhythms of daily life and gather our thoughts about the year ahead, our policy experts have weighed in on what the life sciences sector might expect in 2026.
